The offering is a clear negative for near-term price action due to ~12.6% immediate dilution and a 5% discount placement. However, the extremely strong clinical data (92% ORR) and the $567M cash infusion that extends runway into 2030 to fund a Phase 3 pivotal trial create a strong bull case medium-term. Traders should expect a gap-down at the open on June 11 (closing date), but watch for buying into weakness if the trial data narrative remains intact. The 60-day insider lock-up limits secondary selling pressure.
Price Chart
Executive Summary
Tango Therapeutics is raising approximately $566.5 million in net proceeds through a public offering of 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants to purchase 1,833,395 shares. The offering priced at a 4.9% discount to the prior closing price of $31.56, resulting in immediate and substantial dilution of $24.10 per share to new investors. The capital raise follows highly positive Phase 1/2 clinical data for its lead candidate vopimetostat in combination with RAS inhibitors, showing a 92% objective response rate in pancreatic cancer, which positioned the company to advance into Phase 3 development. The proceeds are expected to fund operations into 2030 including a pivotal trial and potential commercialization. The large dilutive offering paired with very strong clinical data creates a mixed signal for the stock.
Key Facts
- Offering of 18,166,667 shares of common stock at $30.00 per share
- Pre-funded warrants to purchase 1,833,395 shares at $29.999 per warrant
- Net proceeds of approximately $566.5 million ($651.6 million if underwriters exercise full option for 3,000,009 additional shares)
- Offering price at a ~4.9% discount to last sale of $31.56 on June 9, 2026
- Immediate dilution of $24.10 per share to new investors based on net tangible book value
- As adjusted net tangible book value of $5.90 per share post-offering vs offering price of $30.00
- Proceeds expected to fund operations into 2030, including pivotal Phase 3 trial for vopimetostat
- Follows June 8, 2026 data showing 92% ORR in PDAC with daraxonrasib combination and plans to initiate Phase 3
- Underwriters granted 30-day option for additional shares up to 15% of offering
- Insiders and company subject to 60-day lock-up
- ATM facility for up to $35.6 million remains available after lock-up expiration
Financial Impact
~$567M gross capital raise at ~5% discount to market, resulting in ~12.6% dilution to existing shareholders (18.2M new shares vs 144.2M pre-offering outstanding); underwriter fees of ~$33M
Risk Factors
- Immediate dilution of ~12.6% to existing shareholders
- Offering priced at discount to last closing price may pressure stock near-term
- Clinical-stage biotech with no approved products or current revenue
- No clinical trial supply agreement in place yet for Phase 3 daraxonrasib combination
- Dependence on third-party collaborators for drug supply (Revolution Medicines, Erasca)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-266074 |
| Document: d151329dexfilingfees.htm | 0001193125-26-266074 |
| Document: 0001193125-26-266074-index-headers.html | 0001193125-26-266074 |
| Document: 0001193125-26-266074-index.html | 0001193125-26-266074 |
| Document: 0001193125-26-266074.txt | 0001193125-26-266074 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $25.58 $25.20 | ▲ +1.49% | ▲ +1.04% | $23.20 (+9.28%) |
Aug 11, 2026 7w ago | 8-K | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 11, 2026 7w ago | Press Release | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 9, 2026 7w ago | Institutional Cluster | $27.67 $25.29 | ▼ −8.60% | ▼ −8.55% | $23.20 (−16.14%) |
Aug 6, 2026 8w ago | 8-K | $27.07 $25.60 | ▼ −5.43% | ▼ −5.83% | $23.20 (−14.28%) |
Jun 11, 2026 16w ago | 144 | $30.94 $27.97 | ▼ −9.60% | ▼ −10.27% | $23.20 (−25.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 424B5 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 144 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access